Trial Profile
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Talniflumate in Cystic Fibrosis Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2019
Price :
$35
*
At a glance
- Drugs Talniflumate (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genaera Corporation
- 12 Jul 2019 Status changed from recruiting to completed.
- 18 Jul 2014 New trial record